SCHEMBL25324757

SCHEMBL25324757

CCOC(=O)c1c(C)nc(-c2cccc(C#N)c2)n1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F11 P03951 1/20 0.59
GRM5 P41594 1/20 0.48
TLR8 Q9NR97 1/20 0.47
TLR7 Q9NYK1 1/20 0.47
FNTA P49354 1/20 0.46
FNTB P49356 1/20 0.46
CNR2 P34972 1/20 0.46
HRH2 P25021 1/20 0.45
HRH1 P35367 1/20 0.45
ELANE P08246 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
GRIA2 P42262 1/20 0.44
GRIA4 P48058 1/20 0.44
ADORA2A P29274 1/20 0.44
ALOX12 P18054 1/20 0.43
MAPK1 P28482 2/20 0.43
POLB P06746 1/20 0.43
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
PIN1 Q13526 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25325875 0.88 F11 (0.72) F11GRM5TLR8TLR7FNTA
SCHEMBL25326106 0.87 F11 (0.58) F11GRM5TLR8TLR7FNTA
SCHEMBL25329102 0.87 F11 (0.58) F11GRM5TLR8TLR7FNTA
SCHEMBL25326098 0.84 F11 (0.55) F11GRM5TLR8TLR7FNTA
SCHEMBL26108356 0.84 F11 (0.77) F11GRM5GRIA2GRIA4ALOX12
SCHEMBL26488391 0.84 F11 (0.52) F11GRM5TLR8TLR7FNTA
SCHEMBL25328067 0.84 F11 (0.54) F11GRM5TLR8TLR7FNTA
SCHEMBL30771626 0.84 F11 (0.56) F11GRM5TLR8TLR7FNTA
SCHEMBL25326084 0.84 F11 (0.56) F11GRM5TLR8TLR7FNTA
SCHEMBL25915053 0.84 F11 (0.54) F11GRM5TLR8TLR7FNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114105881-B Platelet aggregation inhibitor, and preparation method and application thereof 沈阳海诺威医药科技有限公司 2024-01-26 CN claimed
EP-3960734-B1 PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP claimed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US claimed
CN-114105881-A Platelet aggregation inhibitor and preparation method and application thereof 沈阳海诺威医药科技有限公司 2022-03-01 CN claimed
CN-114105881-B Platelet aggregation inhibitor, and preparation method and application thereof 沈阳海诺威医药科技有限公司 2024-01-26 CN disclosed
EP-3960734-B1 PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP disclosed
EP-3960734-B1 PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP disclosed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US disclosed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US disclosed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US disclosed
CN-114105881-A Platelet aggregation inhibitor and preparation method and application thereof 沈阳海诺威医药科技有限公司 2022-03-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof TFPI, F12, TFPI2 F11 7/4885GRM5 4442/4885TLR8 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.